determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered?

Publikation: Bidrag til tidsskrift › Review › Forskning

Standard

determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered? / Juul, Anders.

I: Hormone Research, Bind 51, 1999, s. 141-148.

Publikation: Bidrag til tidsskrift › Review › Forskning

Harvard

Juul, A 1999, 'determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered?', Hormone Research, bind 51, s. 141-148.

APA

Juul, A. (1999). determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered? Hormone Research, 51, 141-148.

Vancouver

Juul A. determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered? Hormone Research. 1999;51:141-148.

Author

Juul, Anders. / determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered?. I: Hormone Research. 1999 ; Bind 51. s. 141-148.

Bibtex

@article{0a39b7138c314fcd8109000043f1a1c0,
title = "determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered?",
author = "Anders Juul",
year = "1999",
language = "English",
volume = "51",
pages = "141--148",
journal = "Hormone Research",
issn = "0301-0163",
publisher = "S./Karger AG",

}

RIS

TY - JOUR

T1 - determination of insulin-like growth factor-I in the monitoring of GH treatment with respect to effiicacy and side effects. Should potential risks of cardiovascular disease and cancer be considered?

AU - Juul, Anders

PY - 1999

Y1 - 1999

M3 - Review

VL - 51

SP - 141

EP - 148

JO - Hormone Research

JF - Hormone Research

SN - 0301-0163

ER -

ID: 48484236